These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23414115)

  • 1. An analysis of the relative risk for goitre in euthyroid patients with type 2 diabetes.
    Díez JJ; Iglesias P
    Clin Endocrinol (Oxf); 2014 Mar; 80(3):356-61. PubMed ID: 23414115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between serum thyrotropin concentrations and metformin therapy in euthyroid patients with type 2 diabetes.
    Díez JJ; Iglesias P
    Clin Endocrinol (Oxf); 2013 Apr; 78(4):505-11. PubMed ID: 22686474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort.
    Baur DM; Klotsche J; Hamnvik OP; Sievers C; Pieper L; Wittchen HU; Stalla GK; Schmid RM; Kales SN; Mantzoros CS
    Metabolism; 2011 Oct; 60(10):1363-71. PubMed ID: 21081242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An analysis of the relative risk for hypothyroidism in patients with Type 2 diabetes.
    Díez JJ; Iglesias P
    Diabet Med; 2012 Dec; 29(12):1510-4. PubMed ID: 22507223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discontinuation of metformin in type 2 diabetes patients treated with insulin.
    Wulffelé MG; Kooy A; Lehert P; Bets D; Oom JA; Borger van der Burg B; Donker AJ; Stehouwer CD
    Neth J Med; 2002 Jul; 60(6):249-52. PubMed ID: 12365468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease.
    Donadon V; Balbi M; Mas MD; Casarin P; Zanette G
    Liver Int; 2010 May; 30(5):750-8. PubMed ID: 20331505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of emergency department and outpatient visits for hypoglycemia in type 2 diabetes: an analysis of a large US administrative claims database.
    Simeone JC; Quilliam BJ
    Ann Pharmacother; 2012 Feb; 46(2):157-68. PubMed ID: 22234990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
    Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
    Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort.
    Wahlqvist ML; Lee MS; Hsu CC; Chuang SY; Lee JT; Tsai HN
    Parkinsonism Relat Disord; 2012 Jul; 18(6):753-8. PubMed ID: 22498320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined metformin and insulin therapy for patients with type 2 diabetes mellitus.
    Ponssen HH; Elte JW; Lehert P; Schouten JP; Bets D
    Clin Ther; 2000 Jun; 22(6):709-18. PubMed ID: 10929918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy of steady-dose metformin in type 2 diabetes mellitus: a retrospective study.
    Drzewoski J; Czupryniak L
    Med Sci Monit; 2003 Jun; 9(6):CR240-3. PubMed ID: 12824953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of lipid profiles and lipoprotein a levels in patients with type 2 diabetes mellitus during oral hypoglycemic or insulin therapy.
    Habib SS; Aslam M; Naveed AK; Razi MS
    Saudi Med J; 2006 Feb; 27(2):174-80. PubMed ID: 16501671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin reduces risk of benign nodular goiter in patients with type 2 diabetes mellitus.
    Tseng CH
    Eur J Endocrinol; 2019 Jun; 180(6):365-372. PubMed ID: 30986765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of Metformin treatment in obese insulin-resistant patients with euthyroid goiter.
    Răcătăianu N; Bolboacă SD; Sitar-Tăut AV; Mârza S; Moga D; Valea A; Ghervan C
    Acta Clin Belg; 2018 Oct; 73(5):317-323. PubMed ID: 29452573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic and non-iodine-related factors in the aetiology of nodular goitre.
    Knudsen N; Brix TH
    Best Pract Res Clin Endocrinol Metab; 2014 Aug; 28(4):495-506. PubMed ID: 25047201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does metformin have a "buffer effect" on serum TSH levels in euthyroid diabetic patients?
    Santos-Palacios S; Brugos-Larumbe A; Guillén-Grima F; Garmendia-Madariaga A; Galofré JC
    Hormones (Athens); 2015; 14(2):280-5. PubMed ID: 25553761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type 2 diabetes mellitus and hypothyroidism: the possible influence of metformin therapy.
    Distiller LA; Polakow ES; Joffe BI
    Diabet Med; 2014 Feb; 31(2):172-5. PubMed ID: 24151823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between metformin and frailty syndrome in elderly people with type 2 diabetes.
    Sumantri S; Setiati S; Purnamasari D; Dewiasty E
    Acta Med Indones; 2014 Jul; 46(3):183-8. PubMed ID: 25348180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.